MedTrace Logo

Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration

NCT07428798 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-02-24

No results posted yet for this study

Summary

This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD).

PRP is derived from the patient's own blood and contains growth factors that may support cell survival and tissue repair. These factors are thought to help reduce retinal cell loss and slow disease progression.

Three PRP injections were administered to the better-seeing eye at 4-week intervals, while the fellow eye served as an untreated control. Participants were followed from baseline to 10 weeks (two weeks after the third injection).

The aim is to compare changes in RPE atrophy area, photoreceptor loss, and visual function between treated and untreated eyes.

Conditions

Interventions

PROCEDURE

Subtenon Autologous Platelet-Rich Plasma Injection

Autologous platelet-rich plasma prepared from the participant's peripheral blood is administered via subtenon injection under sterile conditions. Each treated eye receives three injections at monthly intervals.

Sponsors & Collaborators

  • Marmara University Pendik Training and Research Hospital

    lead OTHER

Principal Investigators

  • Nimet Zeynep Tıraş, Medical Doctor · Marmara University Faculty of Medicine, Department of Ophthalmology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07428798 on ClinicalTrials.gov